ARTICLE | Finance
Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal
First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
August 19, 2022 10:24 PM UTC
Carlyle’s first late-stage biotech deal since its acquisition of Abingworth will be part of a $260 million funding package for Opthea to conduct Phase III testing of a selective VEGF inhibitor in ophthalmology.
The company said it was the largest-ever financing for an Australian biotech; there are none larger in BioCentury’s BCIQ database...
BCIQ Company Profiles